United Therapeutics Corp

XMUN:UTH

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

United States of America US

Employees

1 400

IPO date

Jun 17, 1999

United Therapeutics is a biotechnology company focused on serious, long-term diseases where patients often need ongoing treatment. Its main business is making medicines for pulmonary hypertension, a condition that raises blood pressure in the lungs and can become life threatening. The company also works on organ manufacturing and transplant-related technologies, which reflects its goal of finding treatments for patients with very limited options.

The company sells prescription drugs to doctors, hospitals, specialty pharmacies, and patients who need chronic therapy. Its revenue mainly comes from drug sales, especially branded therapies used over long periods rather than one-time treatments. Because these medicines are often prescribed by specialists and managed through complex care channels, the company depends on deep relationships with pulmonary hypertension centers, transplant specialists, and specialty distributors.

What makes United Therapeutics different is that it sits at the intersection of rare-disease drug development and transplant medicine. It is not a broad pharmaceutical company with many everyday drugs; instead, it concentrates on a narrow set of severe conditions and builds expertise around them. That gives it a business model tied to specialized physicians, careful patient management, and treatment areas where medical need is high and alternatives are limited.